Daniel Brown is a partner in the New York office of Latham & Watkins and a member of the firm's Litigation & Trial Department. Mr. Brown focuses on patent litigation with a particular emphasis on chemical, pharmaceutical and life sciences litigation. Mr. Brown has also litigated patent cases across a variety of other industries, as well as trademark, copyright, trade secret and commercial business cases. In addition, Mr. Brown has extensive cross-disciplinary experience in areas including complex business and licensing transactions, due diligence and investigations, FDA/regulatory and antitrust.
Mr. Brown is one of the country’s leading litigators in pharmaceutical cases arising under the Hatch-Waxman Act and has been recognized by The Legal 500 US as one of the "'best patent lawyers in the Hatch-Waxman industry.'" He regularly serves as lead trial and appellate counsel for prominent specialty and generic pharmaceutical companies. In nearly two decades of experience, Mr. Brown has litigated successfully more than thirty Hatch-Waxman patent cases that resulted in either favorable judgments or settlement permitting product launch. These litigations have involved many prominent pharmaceutical products, such as Travatan ®, Travatan Z ®, Ultram ER ®, Keppra XR ®, Focalin XR ®, Eloxatin ®, Starlix ®, Ultracet ®, Loprox ®, Imitrex ®, Megace ®, Buspar ®, Wellbutrin SR ®, Zyban ® and many others.
Mr. Brown’s experience also includes complex litigation involving simultaneous patent, antitrust and FDA litigation, patent litigation parallel with Patent Office reissue, reexamination, and interference proceedings and coordination of litigation proceedings in multiple countries. Mr. Brown is frequently involved in FDA strategy and counseling, including filing or responding to citizen petitions, and coordinating FDA strategy with litigation strategy.